The Global Ventricular Tachycardia Market is estimated to be valued at USD 15.52 Bn in 2025 and is expected to reach USD 22.28 Bn by 2032, reflecting a compound annual growth rate (CAGR) of 5.3% from ...

Topline results from the ASPIRE Phase 2b study expected in mid-2026 with operating runway through 2027Series B extension was led by Arkin Bio Capital and Monograph Capital, with participation from ...

Last year, the U.S. Food and Drug Administration approved a new drug — suzetrigine — the first truly new kind of painkiller ...

Latigo Biotherapeutics Inc. has synthesized sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers. They are reported to be useful for the treatment of pain, cough and pruritus.

"The main side effect is them not working! Not everyone responds to every drug." The common blood pressure drug you may want ...

Review clinical classifications, diagnostic procedures, and management strategies for cardiomyopathy and heart failure in this comprehensive overview.

Scientists are racing to redesign how powerful painkillers work, aiming to keep the relief that opioids provide while ...

Jumpcan Pharmaceutical Group Ltd. has divulged sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

I hear paternal grumbling at what I’m about to say. Dr. Gifford-Jones often warned we are a “nation of wimps” when it comes ...

Researchers are uncovering how disrupted glutamatergic synapses drive diverse forms of intellectual disability, revealing new ...

SaveHealth reports on 10 hypertension medications, their classifications, effectiveness, side effects, and safety in managing ...